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Today we are beginning to understand how phytochemicals can influence metabolism, cellular signaling and gene
expression. The hydroxybenzoic acids are related to salicylic acid and salicin, the first compounds isolated that have
a pharmacological activity. In this review we examine how a number of hydroxyphenolics have the potential to
ameliorate cardiovascular problems related to aging such as hypertension, atherosclerosis and dyslipidemia. The
compounds focused upon include 2,3-dihydroxybenzoic acid (Pyrocatechuic acid), 2,5-dihydroxybenzoic acid
(Gentisic acid), 3,4-dihydroxybenzoic acid (Protocatechuic acid), 3,5-dihydroxybenzoic acid (α-Resorcylic acid) and
3-monohydroxybenzoic acid. The latter two compounds activate the hydroxycarboxylic acid receptors with a
consequence there is a reduction in adipocyte lipolysis with potential improvements of blood lipid profiles. Several
of the other compounds can activate the Nrf2 signaling pathway that increases the expression of antioxidant
enzymes, thereby decreasing oxidative stress and associated problems such as endothelial dysfunction that leads to
hypertension as well as decreasing generalized inflammation that can lead to problems such as atherosclerosis. It
has been known for many years that increased consumption of fruits and vegetables promotes health. We are
beginning to understand how specific phytochemicals are responsible for such therapeutic effects. Hippocrates’
dictum of ‘Let food be your medicine and medicine your food’ can now be experimentally tested and the results of
such experiments will enhance the ability of nutritionists to devise specific health-promoting diets.
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The identification of salicin and salicylic acid as the chem-
ical compounds that gave willow bark its analgesic and
antipyretic properties initiated the development of the
modern pharmaceutical industry and pharmaceuticals now
dominate the therapeutic interventions of modern Western
(allopathic) medicine. During the past few centuries there
have been major breakthroughs in understanding the role
of foods in the maintenance of life, including: i) the identi-
fication of carbohydrates, lipids and proteins and their
roles in maintaining the metabolic machinery of our bod-
ies, ii) the identification of vitamins and minerals and their
roles in metabolism. The past century also led to major* Correspondence: pganguly@alfaisal.edu
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unless otherwise stated.breakthroughs in understanding cellular signaling pathways
and the control of gene expression. We are now beginning
to understand how components in our foods, mainly cer-
tain phytochemicals, are affecting cellular signaling thereby
influencing metabolism as well as gene expression. We are,
thus, on the cusp of the third era of nutrition where we will
understand the roles that particular phytochemicals can
play in altering metabolism and gene expression that leads
to better health [1]. In this review we consider the possible
therapeutic effects of hydroxybenzoic acids that chemically
are closely related to the first identified pharmaceuticals,
salicin and salicylic acid. These compounds either decrease
oxidative stress and inflammation through promotion of
the expression of antioxidant enzymes or they inhibit
adipocyte lipolysis through activation of hydroxycar-
boxylic acid receptors, thereby potentially promoting
better plasma lipid profiles. Of course, everything is
double-edged and phytochemicals may also affect thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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metabolize xenobiotics, including drugs. The past has
shown us that if one were taking the calcium channel
blocker felodipine it becomes important for one’s health
not to consume grapefruit [2]. Thus, if one were to alter
diet to increase intake of particular phytochemicals, it be-
comes important to know how such phytochemicals affect
the function of phase 1 enzymes.
A major aim of this review is to interest researchers in
the area of nutrition to investigate how phytochemicals in-
fluence cellular signaling and gene expression so that rapid
progress can be made in the science of Hippocrates’ dic-
tum: ‘let food be your medicine and medicine your food’.
Review
Discovery of salicin and salicylic acid
The first pharmacologically-active drugs isolated from a
herbal preparation were identified during the nineteenth
century [3]. These were the analgesics salicin (2-(hydroxy-
methyl)phenyl-β-D-glucopyranoside) and its metabolite sali-
cylic acid (2-hydroxybenzoic acid) (Figure 1): these were
obtained from willow bark extracts [3]. The analgesic and
antipyretic activities of willow bark extracts were known far
earlier, being mentioned in Egyptian and Sumerian texts [4].
During the latter part of the nineteenth century salicylic acid
was acetylated to form the more gastrointestinal-friendly
non-steroidal anti-inflammatory drug acetylsalicylic acid
(ASA or 2-[acetyloxyl]benzoic acid), commonly referred to
as aspirin. Although used since the end of the nineteenth
century the mechanisms of action of aspirin were only be-
ginning to be discovered in the 1970s where it was demon-
strated that aspirin inhibited the action of cyclooxygenase
(COX) thereby inhibiting the synthesis of pro-inflammatoryFigure 1 Structures of salicin, salicylic acid and acetylsalicylic
acid (2-[acetyloxyl]-benzoic acid). Chemical diagrams taken from
Wikimedia Commons.eicosanoids [5]. More recently it has been shown that as-
pirin also promotes the acetylation of COX2 resulting in the
promotion of the synthesis of 15-hydroxyeicosatetraenoic
acid that is converted into the anti-inflammatory eicosanoid
15-epi-lipoxin A4 [6].
Following the discovery of salicin and synthesis of as-
pirin a large pharmaceutical industry arose around the
identification and isolation of the pharmacologically-active
compounds present in herbal medicines, with often modi-
fication of such active compounds to form the drugs cur-
rently in clinical use. Soon pharmaceuticals dominated the
therapeutic interventions of Western (allopathic) medicine.
Forgotten was Hippocrates’ dictum: “Let food be your
medicine and medicine your food”. This article is primarily
aimed at discussing the possible roles of the isomers of
dihydroxybenzoic acid, that are present in certain fruits and
vegetables, in preventing cardiovascular diseases.
Pharmacologically active compounds in foods that we eat
Recently it has become recognized that pharmacologically
active compounds are present not only in herbal products
but also in many of our foods; hence, foods, in principle,
could, as stated by Hippocrates, be used in preventing, if
not treating, many diseases, particularly diseases related to
lifestyle that become more common with age.
One of the earliest identified pharmacologically active
components in food is the isothiocyanate sulforaphane,
which is a metabolite of the sulforaphane glucosinolate,
also known as glucoraphanin [7]. Sulforaphane glucosino-
late is present in crucifers and is present in very high levels
in broccoli sprouts of particular cultivars [8]. Sulforaphane
is a very potent activator of nuclear factor (erythroid-de-
rived-2)-like-2 [Nrf2]) [9] through oxidation of the thiols
of the protein Kelch-ECH-Associated Protein 1 (Keap1)
that normally sequesters Nrf2 in the cytoplasm [10]. Nrf2
promotes the expression of genes whose protein products
either promote scavenging of oxidants or decrease the
likelihood of oxidant production [11,12]. A more oxidizing
environment results in many physiological problems. For
example, a more oxidizing environment results in readier
activation of the transcription factor complex nuclear fac-
tor kappa B (NFκB) [13] that, in turn, promotes expression
of pro-inflammatory genes.
Broccoli sprouts rich in sulforaphane glucosinolate have
been shown to reduce oxidative stress and inflammation
in hypertensive rats thereby promoting better endothelial
function and lower blood pressure [14]. A similar effect is
seen when rats are given sulforaphane by gavage [15], indi-
cating that the health-promoting effects of broccoli
sprouts is due to the sulforaphane metabolite of the gluco-
sinolate rather than some other component that may be
present. Furthermore, the less oxidative stress and inflam-
mation in pregnant hypertensive rats fed with broccoli
sprouts results in less oxidative stress, inflammation and
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spring do not have a diet rich in Nrf2 activators [16]. Thus,
diet can have positive effect on fetal determinants of adult
health. We, clearly, are now in the third era of nutritional
research and are beginning to understand how specific phy-
tochemicals affect cell signaling and gene expression and,
thereby, health [1].
A concern may arise whether the increase in consump-
tion of foods that have increased Nrf2 activity may be
harmful. As far as sulforaphane glucosinolate is concerned
phase 1 clinical trials in human have indicated no ontoward
effect on liver and thyroid function when ingesting broccoli
sprout extracts rich in sulforaphane glucosinolate [17]. Fur-
thermore, another human trial in type 2 diabetics has
shown that consuming a broccoli sprout extract containing
either 112.5 or 225 micromoles of sulforaphane glucosino-
late significantly decreased fasting glucose and insulin levels
[18], demonstrating that food sources can be used as a
medicine. Finally, the Juurlink laboratory has shown that
intake of 10 μmol sulforaphane/kg body weight by gavage
for 4 months had no detectable negative effect on the
Stroke-prone spontaneously hypertensive rats [15], nor
did consumption of broccoli sprouts containing 5–10 μmol
sulforaphane equivalents/Kg body weight have any effect
on the normal physiology Sprague Dawley rats [14]; thus,
compounds that are Nrf2 activators appear to have
physiological effects only in individuals that are under
oxidative stress. Intake of sulforaphane tips the cell to a
more normal redox state thereby decreasing the prob-
ability of problems related to inflammation. For a more
detailed look at how the Nrf2 system influences cardio-
vascular health, please see [12].
Surprisingly, although there are over a thousand papers
examining the positive effects of sulforaphane in prevent-
ing cancer, treating cancer, decreasing oxidative stress or
treating conditions with an underlying oxidative stress and
inflammatory component, there are no toxicology studies
reported for this compound. Sulforaphane is an electro-
phile and like other electrophiles it oxidizes thiols. How-
ever, unlike other electrophiles such as dimethyl fumarate,
sulforaphane - as well as certain other phytochemicals -
has the particular electro-geometry that allows oxidation
of Keap1 thiols at submicromolar concentrations. Thus,
50 nM sulforaphane has the same ability to increase Nrf2-
inducible protein expression [19] as 25 μM dimethyl fu-
marate [20]: in other words, 500 times as many thiols are
oxidized by dimethyl fumarate, a drug recently approved
as a treatment for multiple sclerosis [21], to obtain the
same Nrf2 activation as 50 nM sulforaphane.
Keap1 thiols are not the only thiols oxidized by sulfo-
raphane and one might anticipate that sulforaphane ought
to interfere with many cellular functions. In an attempt to
address this, Piberger and colleagues examined the ability
of sulforaphane to release zinc from a synthetic peptidethat resembled the zinc-binding domain of xeroderma pig-
mentosum A [22]. They demonstrated that sulforaphane at
concentrations of 50 μM or greater caused zinc release
from the peptide; however, they also demonstrated that
lower levels of sulforaphane (5 μM) interfered with the
xeroderma pigmentosum A-dependent nucleotide excision
repair. It is unlikely that plasma levels of sulforaphane can
reach 5 μM through dietary intake of sulforaphane gluco-
sinolate. Indeed, male spontaneously hypertensive stroke-
prone rats fed daily a dried broccoli sprouts containing 14.5
micromoles of sulforaphane equivalent only achieved a
plasma level of 0.5 μM dithiocarbamate [23], the sulforaph-
ane metabolite. One must also keep in mind that unlike in
cell culture studies where there is a constant concentration
of the compound of interest, dietary intake of sulforaphane,
whether through food consumption or through gavage, re-
sults in fluctuating plasma levels where peak concentra-
tions can result in sustained elevations of anti-oxidant
proteins through activation of the Nrf2 system but only
transient inactivation of the function of proteins such as
xeroderma pigmentosum A. Clearly, there is an abun-
dance of evidence, both epidemiological and experimental
that is in support of the ability of sulforaphane’s health-
promoting activities [24].
Concerns with increasing consumption of
pharmacologically active compounds found in our foods
The knowledge of which particular cultivar one is con-
suming can be important. For example, various cultivars
of broccoli and other crucifers have different glucosinolate
profiles and a major concern with glucosinolates is that
some of them are goitrogenic [25]; hence, it is important
to ensure that one is increasing sulforaphane glucosinolate
consumption that one does not consume significant quan-
tities of goitrogenic glucosinolates. In the studies by the
Juurlink laboratory the Calabrese variety of broccoli was
used since this cultivar has high levels of sulforaphane glu-
cosinolate and other Nrf2-activating glucosinolates but
low levels of the goitrogenic glucosinolates [14].
Phytochemical compounds may have more than one
mechanism of action. Another major concern is effects of
phytochemicals on the expression and/or activity of the
drug metabolizing phase 1 enzymes, for example, the cyto-
chrome P450s (CYPs). Altering phase 1 enzyme activity can
affect drug metabolism. For example, the flavanone nar-
ingenn activates Nrf2 [26] but it is also a competitive in-
hibitor of CYP3A4 [27]. CYP3A4 is involved in the
metabolism of many commonly used drugs. For ex-
ample, CYP3A4 is involved in the metabolism of felodi-
pine, a calcium channel blocker [28]. If one is taking
felodpine, consuming increased amounts of naringenin
and furanocoumarins present in grapefruit juice may
cause dangerous elevations in the plasma level of felodi-
pine resulting in dangerously low blood pressure. Other
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phase 1 enzyme expression or activity [29], for example,
sulforaphane inhibits CYP3A4 gene expression and in-
hibits CYP1A2 and CYP2E1 [30]. Clearly, if one is on a
medication it becomes important to know the effects of
consuming increasing amounts of foods with pharmaco-
logically active components. Physicians are already aware
that when administering the vitamin K epoxide reductase
inhibitor warfarin, that the dosage required for the desired
pharmacological effect is dependent upon dietary intake of
green leafy vegetables that are rich in vitamin K [31].
Thus, altering diet to increase intake of phytochemicals
that are pharmacologically active will make the life of a
physician or nutritionist more complicated.
The hydroxybenzoic acids
It is 185 years since Henri Leroux first isolated a pure
crystalline form of salicin [3]. It seems timely to revisit
this family of hydroxyphenols in the context of human
health. There are a number of dihydroxybenzoic acid
(DHBA) compounds, related to salicylic acid, that are also
pharmacologically active, some of which are metabolites
of salicylic acid. Their chemical formulae are outlined in
[32] and given in Figure 2. The compounds include 2,3-
DHBA (Pyrocatechuic acid or Hypogallic acid), 2,5-DHBA
(Gentisic acid), 2,4-DHBA (β-Resorcylic acid), 2,6-DHBA
(γ-Resorcylic acid), 3,4-DBHA (Protocatechuic acid) and
3,5-DHBA (α-Resorcylic acid) [32,33]. The hydroxyben-
zoic acids are phytochemicals that can be found in certain
of foods and can be also be formed from polyphenols such
as flavonoids by gut bacteria, e.g., [34]. Because they areFigure 2 Structures of the isomers of dihydroxybenzoic acid. Chemicahydroxylated phenolic compounds they all can scavenge
oxidants such as free radicals via their hydroxyl groups
[35], but this is not an important mechanism of action
since essentially one hydroxylated phenolic compound can
scavenge only one or two strong oxidants. Their more in-
teresting properties are associated with their ability to
modify cellular signaling processes that introduces a
multiplier effect, one example is activation of the Nrf2
pathway that results in enhancement of multiple endogen-
ous anti-oxidant mechanisms. We will focus on a few of
these hydroxyphenolic compounds in this review.
2,3-DHBA (Pyrocatechuic acid)
Pyrocatechuic acid is a metabolite of aspirin [33]. It is nor-
mally present in plasma even when there has been no in-
take of aspirin [36], indicating a dietary source of either
2,3-DHBA or a precursor molecule. 2,3-DHBA is present
in several medicinal herbs, including, Madagascar rosy
periwinkle [37] and Boreava orientalis [38] as well as in a
number of fruits such as batoko plum commonly made
into preserves in South and South-East Asia [39], avoca-
dos [40] and cranberries [41,42]. A major dietary source of
pyrocatechuic acid is Aspergillus-fermented soy products,
popular in Japan, that can contain more than 2 mmol 2,3-
DHBA/L soy product [43].
2,3-DHBA decreases hydrogen peroxide-induced activa-
tion of the transcription factor complex nuclear factor
kappa B (NFκB) that plays an important role in inflamma-
tion [44]. The mechanism of action for this effect may be
simple scavenging of hydrogen peroxide [35] or possibly
the activation of the antioxidant response; however, thisl diagrams taken from Wikimedia Commons.
Table 1 Dietary sources of gentisic acid
Source Content* References
Apple 2 μmol/Kg [56]
Beer 2 μmol/L [57]
Bilberries 150 μmol/kg [58]
Bitter melon, ripe 4,220 μmol/Kg [59]
Blackberries 135 μmol/Kg [58]
Blueberries, V. arctostaphylos 1.3 μmol/Kg [60]
Currants, black 155 μmol/Kg [58]
75 μmol/kg [56]
Gooseberries 42 μmol/kg [56]
Grapes, white 2.9 μmol/kg [56]
Honeysuckle, blueberried 150 μmol/Kg [58]
Juneberries, European 220 μmol/Kg [58]
Kiwi, common varieties 585 Mol/Kg [53]
Kiwi, A. Kolomikta, ‘Dr Szymanowski’ 27,610 μmol/Kg [53]
Mulberries, black 112 μmol/Kg [58]
Pear 2.5 μmol/Kg [56]
Strawberries 118 μmol/Kg [56]
Wine, red 3 μmol/L [61]
Wine, white 1 μmol/L [61]
*Values given are for the free phenolic as well as the phenolic derived from
either esters or glycosides. All published values converted to μmoles per unit
volume or per Kg fresh fruit (based upon an 85% water content).
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this hydroxybenzoic acid metabolite, although other
dihydroxybenzoic acids have this ability. Nor has there
been examination of the possible effects of 2,3-DHBA
on phase 1 enzyme expression and activity. Administra-
tion of 2,3-DHBA to a rat model of sepsis has been re-
ported to decrease mortality when used in conjunction
with gentamycin [45], likely through decreased tissue
damage related to oxidative stress and associated in-
flammation. Relatively little is known about the distri-
bution of 2,3-DHBA in the plant kingdom nor its
mechanism of therapeutic action but both seem worthy
of further investigation.
2,5-DHBA (gentisic acid)
Gentisic acid like aspirin inhibits prostaglandin formation
in response to lipopolysaccharides [46], presumably via
inhibiting COX activity. This suggests that foods rich in
gentisic acid may help decrease the probability of heart at-
tacks due to clot formation. Gentisic acid also inhibits the
oxidation of low-density lipoprotein and inhibits the for-
mation of lipid hydroperoxides [47,48] and, thus, de-
creases the probability of atherogenesis. These effects of
gentisic acid are usually attributed to its ability to scavenge
free radicals and other oxidants; however, gentisic acid is
also an Nrf2 activator [49] and this is the most likely rele-
vant mechanism. In the study by Yeh and Yen [49], genti-
sic acid was introduced into the diet whereby rats
consumed very high amounts of gentisic acid (650 μmol/
Kg/day) - what plasma levels were achieved was not mea-
sured. Clearly, dose–response studies are required to de-
termine whether gentisic acid activates the Nrf2 system at
much lower dietary intakes. Also, at high concentrations
gentisic acid is an aldose reductase inhibitor but the IC50
is over 200 μM [50], concentrations that are likely not at-
tainable via the diet. How, and whether, gentisic acid af-
fects phase 1 enzyme gene expression and activity is not
known. CYP2E1 and CYP3A4 are involved in the metab-
olism of gentisic acid [51].
Gentisic acid is widely present in foods we consume, in-
cluding cereals such as wheat and rye [52], actinidia (e.g.,
kiwi) fruit [53], aloe vera [54], a number of mushrooms
[55] as well as other sources. For quantitative data on gen-
tisic acid distribution in food sources see Table 1.3,4-DHBA (protocatechuic acid)
Protocatechuic acid is widely distributed, in our foods be-
ing found in buckwheat [62], mustard [63], nipa palm nut
[64], kiwi fruit [65], currents [66], blackberries and straw-
berries [67], Jujube fruit [68], chokeberries [69], mango
[70]. In addition, it is also found in chicory, olives, dates,
grapes, cauliflower, lentils, etc. [71]. For quantitative data
on protocatechuic acid in food sources see Table 2.Protocatechuic acid has anti-inflammatory activity [71]
and activates Nrf2 [69] through Jun kinase (JNK) modifi-
cation of the Nrf2 signalling system [83]. In this in vitro
study, 25 μM protcatechuic acid was used. However, a
lower concentration (3 μM) demonstrated an enhance-
ment in the antioxidant defense systems [84]. In another
in vitro assay the concentration of protocatechuic acid re-
quired to double the quinone oxireductase activity in mur-
ine hepatoma cells was 4.3 μM [69]. These studies suggest
that diet may result in plasma protcatechuic acid levels
sufficient to enhance the antioxidant defense systems. Pro-
tocatechuic acid also has antihyperglycemic effects in
streptozotocin-induced diabetic rats [85], possibly through
activation of the Nrf2 system. For a detailed discussion on
the potential role of protocatechuic acid in preventing dis-
ease or treating disease see [71].
3-Monohydroxybenzoic Acid (3-MHBA) and
3,5-Dihydroxybenzoic Acid (α-Resorcylic Acid)
The final compounds to be considered are 3-MHBA
(also known as m-hydroxybenzoic acid) and 3,5-DHBA
since there is an intriguing article demonstrating that
they are agonists of the hydroxycarboxylic acid receptors
HCA1 and HCA2 [86]. The HCA receptor family is G-
protein coupled (Gi) and comprised of three members:
HCA1, HCA2 and HCA3 [86] predominantly expressed
Table 2 Dietary sources of protocatechuic acid
Source Content* References
Açai pulp 11.7 μmol/L [72]
Apple 31 μmol/Kg [56]
Avocado 2.4 μmol/Kg [73]
Beer 3 μmol/L [57]
Bilberries 111 μmol/Kg [58]
Bitter melon, ripe 970 μmol/Kg [59]
Blackberries 127 μmol/Kg [58]
Blueberries, V. arctostaphylos 9.5 μmol/kg [60]
Buckwheat, whole grain 600 μmol/Kg [62]
Cauliflower, raw 29 μmol/Kg Phenol-Explorer†
Chicory 1,090-1,415 μmol/Kg Phenol-Explorer
Currants, black 78 μmol/Kg [58]
357 μmol/Kg [56]
Dates, dried 320 μmol/kg Phenol-Explorer
Eggplant, purple, raw 48 μmol/Kg Phenol-Explorer
Garlic 23 μmol/Kg [74]
Gooseberry 405 μmol/Kg [56]
Grapes, white 22 μmol/Kg [56]
Honeysuckle, blueberried 140 μmol/Kg [58]
Juneberries, European 159 μmol/Kg [58]
Kiwi juice 39 μmol/L [65]
Lentils, dried, dehulled 4.5 μmol/Kg Phenol-Explorer
Lentils, dried with hulls 9 μmol/Kg Phenol-Explorer
Lingonberries 195 μmol/Kg [75]
Mango pulp 2.5 μmol/Kg [73]
Mangosteen pulp 91 μmol/Kg [76]
Medlar, ripe 6 μmol/Kg [77]
Mulberries, black 119 μmol/Kg [58]
Oil, Açai – phenol rich 4 μmol/mL [72]
Oil, olive – virgin 3-11.5 μmol/Kg [78]
Olive, black, raw 390 μmol/kg Phenol-Explorer
Olive, green, raw 43 μmol/Kg Phenol-Explorer
Onion, red 130 μmol/Kg Phenol-Explorer
50 μmol/Kg [74]
Onion, white 65 μmol/Kg Phenol-Explorer
1.2 μmol/Kg [74]
Pear 3 μmol/Kg [56]
Raspberry 270 μmol/Kg [56]
Shallot 65 μmol/Kg Phenol-Explorer
Sorghum 165 μmol/Kg Phenol-Explorer
Strawberry 112 μmol/Kg [56]
Table 2 Dietary sources of protocatechuic acid (Continued)
Star anise 2,090 μmol/Kg Phenol-Explorer
Wine, red 0.3-0.8 μmol/L [79]
Wine, white 0.1-0.5 μmol/L [79]
*Values given are for the free phenolic as well as the phenolic derived from either
esters or glycosides. All published values converted to μmoles per unit volume or
per Kg fresh fruit (based upon an 85% water content) or per Kg grain.
†References for Phenol-Explorer are: [80-82].
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olysis. They were formerly classified within the nicotinic
acid receptor family. The natural ligand for HCA1 ap-
pears to be lactic acid (EC50 = 1.3-4.8 mM) whose nor-
mal plasma concentrations (in low mM range) can
activate HCA1 to decrease lipolysis. The natural ligand
for HCA2 is 3-hydroxybutyric acid (EC50 = 0.7-0.8 mM)
whose plasma levels can reach 6–8 mM during fasting.
Nicotinic acid also acts as a ligand for HCA2 and has
been used pharmacologically to treat dyslipidemia [87],
although it has an associated flushing problem. The nat-
ural ligand for HCA3 is 3-hydroxyoctanoic acid (EC50 =
4–8 μM) whose levels rise during starvation and diabetic
ketosis [86]. These receptors are, thus, intimately in-
volved in the feedback mechanisms regulating lipolysis.
3-MHBA is an agonist for both HCA1 (EC50 of
186 μM) and HCA2 (EC50 of 158 μM while 3,5-DHBA is
a specific agonist for HCA2 (EC50 of 172 μM). Activat-
ing HCA1 and HCA2 inhibits lipolysis in adipocytes
[86]. These data suggest that altering diet to include 3-
MHBA and/or 3,5-DHBA may help control dyslipede-
mia. However, little information is available regarding
the presence of these hydroxybenzoic acid compounds
in the plants we eat. A little more is known about 3-
MHBA (see Table 3) than 3,5-DHBA.Important sources of hydroxybenzoic acids are microbial
metabolites of more complex phenolics
Zhang and colleagues used a commercial cranberry drink
to determine the proportion of dietary phenolics trans-
ferred to the blood [41]. The cranberry drink was com-
prised of 27% juice and contained 2.41 μg 2,3-DHBA/mL
[41] with a total of 1800 mL consumed by each test sub-
ject (i.e., a total of 438 μg or 2.84 μmoles 2,3-DHBA).
After 45 minutes blood was taken and plasma level of phe-
nolics were determined. At this time plasma levels of 2,3-
DHBA was 2.06 μg/mL. Even if the 2,3-DHBA was solely
restricted to plasma and not cells or other body fluids, this
is a greater amount of 2,3-DHBA than what was con-
sumed. One can only conclude that there is metabolism of
other phenolics to 2,3-DHBA, likely by gut bacteria. In-
deed, there is an abundance of evidence that gut bacteria
metabolize more complex phenolics such as flavonoids
into simpler phenolics [88].
Table 3 Dietary sources of 3-monohydroxybenzoic acid
Source Content References
Avocado 62 μmol/Kg [73]
Beer 6 μmol/L [57]
Blueberry, V. arctostaphylos 1.5 μmol/Kg [60]
Cranberries, fruit 27 μmol/Kg Phenol-Explorer
66 μmol/L [42]
Medlar, ripe 0.7 μmol/Kg [77]
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which can be an oxidation product of the flavonoid
quercetin [89] as well as a microbial metabolite of cat-
echin [90] and anthocyanins and procyanidins [91].
Humans fed 60 g/day of a black raspberry freeze-dried
powder, rich in anthocyanins, achieved a mean protoca-
techuic acid plasma level of 25 nM [92]. In another
study where human participants ate two portions of a
variety of small berries daily achieved mean protcate-
chuic acid plasma levels of 130 nM [93]. A third study
where elderberry extract containing a total of 500 mg an-
thocyanins was consumed daily, protocatechuic sulfate
plasma levels reached 360 nM three hr after intake [94]. A
fourth study had humans consume 1 liter of blood orange
juice rich in cyanidin glucosides - here a plasma level of
0.5 μM protocatechuic acid was observed 2 hr following
ingestion [91]. Whether intake of protocatechuic acid via
the diet will result in sufficient plasma concentrations to
have a pharmacological effect is not yet demonstrated, but
as noted below perhaps it can have a tipping effect.
Phytochemicals as tipping point compounds rather than
pharmaceuticals
Disease is a deviation from homeostasis. In a ‘normal’ diet
it is rare that one can consume enough of a given food to
achieve a plasma concentration of a specific compound of
interest to have a pharmacologically significant effect.
However, one must keep in mind that we are constantly
consuming foods that have more than one of these com-
pounds that can affect, for example, the Nrf2 system. An
increase in the consumption of anyone of these may be
the tipping point to activate the Nrf2 system sufficiently to
result in cells with a more normalized redox status. For
example, for Nrf2 to translocate from the cytoplasm to the
nucleus requires oxidation of thiols on Kelch-like ECH-
associated protein-1 (Keap1), the protein that anchors
Nrf2 to the cytoskeleton, but the phosphorylation status of
particular amino acid residues on Nrf2 also determines
the efficacy of nuclear translocation [95]. The action of
sulforaphane is oxidation of Keap1 thiols [96], whereas the
action of protocatechuic acid is on the phosphorylation
status of Nrf2 [83]. Thus, protocatechuic acid will enhance
the efficacy of low levels of an inducer such as sulforaph-
ane. It may well be possible that on a background of a dietcontaining low levels of sulforaphane glucosinolate (that
in itself has no significant effect on the activation of the
Nrf2 system) that consuming low levels of protocatechuic
acid may be the tipping point towards activation (i.e., nu-
clear translocation) of the Nrf2 system resulting in a more
normal redox state for cells.
Similarly, the EC50s of 3-MHBA for HCA1 and 3,5-
DHBA for HCA2 suggest that diet cannot influence the
activation state of these hydroxycarboxylic acid receptors.
Although the EC50 is an important measure of activity
since it is a measure of the concentration where 50% of
the receptors are activated, it is not a measure of the kinet-
ics of the binding. Importantly it does not measure the
time a compound occupies and activates the receptor. If,
for example, the 3,5-DHBA-HCA2 dissociation time is sig-
nificantly longer than the lactate-HCA2 dissociation time,
then this effectively lowers that lactate concentration ne-
cessary to activate the HCA2 signalling pathway. It is very
possible that concentrations of the hydroxycarboxylic acid
an order or two below the EC50 will allow lower concen-
trations of the natural ligand to result in physiologically
significant increases in receptor activation states to result
in decreases in lipolysis to significantly affect blood lipid
levels. In other words dietary intake of 3-MHBA and 3,5-
DHBA that result in low μmolar plasma concentrations
may tip the scale towards more normal lipid profiles.
Concluding remarks
We are now at the knowledge tipping point where rather
than having vague guides on eating more fruits and vegeta-
bles to improve health we can design diets to include spe-
cific phytochemicals that influence cellular signaling and
gene expression. For example, diets containing specific
Nrf2 activators that act on Keap1 thiols as well as activators
that act on the phosphorylation states of Nrf2 allowing
more efficient Nrf2 translocation to the nucleus - the end
result is a more normal redox status of cells with conse-
quences that include decreased probabilities of developing
hypertension and developing atherosclerotic lesions. We
can design diets that increase the content of 3-MHBA and/
or 3,5-DHBA that results in tipping to a more normal
blood lipid profile, again decreasing the probability of devel-
oping atherosclerotic lesions. We are at the beginning of
understanding how phytochemicals may influence signaling
pathways that influence cardiovascular health. We trust we
have intrigued the readers sufficiently to do further research
on the distribution, microbial metabolism and uptake of
hydroxybenzoic acids as well as on their potential thera-
peutic actions.
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